Mark Fingerhuth is a scientific ML leader and co-founder of ProteinQure, bringing over eight years of experience in developing and scaling machine learning-driven drug discovery platforms. His work at ProteinQure spans from early research to clinical-stage programs.

A key achievement in his career includes co-creating the first AI-designed peptide to advance into clinical trials, specifically for triple-negative breast cancer. He is also a co-inventor on a patent application.